Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you offer ultra-hypofractionated accelerated partial breast re-irradiation using 5 fractions?
If so, what dose would you use?
Answer from: Radiation Oncologist at Community Practice
I have favored 40 in 15 or 45 in 30 for now in view of reradiation
Sign In
or
Register
to read more
26461
Related Questions
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
Would you feel comfortable doing high tangents with ultra-hypofractionation?
How do you advise women to manage wound care for breast brachytherapy needle sites for long term cosmetic outcomes?
How would you manage an isolated nodal recurrence of breast cancer in a patient with a prior history of mantle-field radiation?
In which patients do you utilize a breast MRI as part of the initial workup for breast cancer?
Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?
Would you offer partial breast radiation to a young breast cancer patient with BRCA 1 if all other criteria are met?
What is your approach to women with breast cancer who opts for a staged approach with up-front lumpectomy and SLN biopsy (pN-) when there are indications for adjuvant radiation therapy but she plans for a later mastectomy (=>6 months)?
How would you approach reirradiation in a patient with a history of whole-breast RT many years ago, now with a small intermediate-grade DCIS s/p lumpectomy with an elevated DCISionRT?
What is your preferred comprehensive nodal irradiation approach in non-metastatic breast cancer patients with underlying respiratory diseases or poor baseline respiratory function in light of the findings from the RadComp Trial?